Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 11/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23213325 | 1.00 | CHRM4 (0.59) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23295183 | 1.00 | CHRM4 (0.59) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213614 | 0.96 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213612 | 0.96 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213050 | 0.90 | CHRM4 (0.60) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213047 | 0.90 | CHRM4 (0.60) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213244 | 0.87 | CHRM4 (0.58) | CHRM4CHRM1CHRM2CHRM5ALDH1A1 | |
| SCHEMBL23213267 | 0.85 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213265 | 0.85 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5KDM4E | |
| SCHEMBL23213668 | 0.84 | CHRM4 (0.61) | CHRM4CHRM1CHRM2CHRM5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140959-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | CHRM4 4/4885CHRM1 2/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.